{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:06:52Z","timestamp":1793783212952,"version":"4.6.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014476","name":"Pfizer Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Heart failure with preserved ejection fraction (HFpEF) represents a\u00a0heterogeneous syndrome characterised by various underlying aetiologies, such as transthyretin amyloid cardiomyopathy (ATTR-CM). The aim of this study was to determine the true prevalence of ATTR-CM in a\u00a0Dutch all-comers cohort of HFpEF patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>From 2018 to 2023, all patients diagnosed with HFpEF underwent prospective screening for ATTR-CM. Diagnosis of ATTR-CM was made in accordance with guideline recommendations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of the 202 HFpEF patients included (mean\u202f\u00b1\u2009standard deviation age: 76\u202f\u00b1\u20097\u00a0years; 64% female), 9\u00a0(5%) showed cardiac uptake on scintigraphy, of whom 6\u00a0(3%) were subsequently diagnosed with wild-type ATTR-CM. Left ventricular wall thickness (LVWT) was significantly higher in ATTR-CM patients than non-amyloid HFpEF patients (median interventricular septum diameter: 15\u202fmm; interquartile range (IQR): 11\u201317 vs 10\u202fmm; IQR: 9\u201311; <jats:italic>p<\/jats:italic>\u202f&lt;\u20090.001). Interestingly, 2\u00a0ATTR-CM patients (33%) did not have increased LVWT at the time of diagnosis. These\u00a02\u00a0patients were in a\u00a0less advanced prognostic stage.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>\n              <jats:italic>Conclusion<\/jats:italic>\n            <\/jats:title>\n            <jats:p>This study revealed a\u00a0low prevalence of ATTR-CM (3%) in an unselected HFpEF cohort. We identified ATTR-CM patients without increased LVWT (33%), who presented at an earlier disease stage. Hence, relying exclusively on LVWT for the diagnosis of ATTR-CM may result in delayed and\/or missed diagnoses.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12471-025-01954-3","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T11:15:35Z","timestamp":1745838935000},"page":"193-198","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prevalence of transthyretin amyloid cardiomyopathy in an unselected cohort with heart failure with preserved ejection fraction"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0763-7551","authenticated-orcid":false,"given":"Anouk","family":"Achten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa P. M.","family":"van Empel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerremy","family":"Weerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne","family":"Mourmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Brunner-La Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Sanders-van Wijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Knackstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"1954_CR1","first-page":"102","volume":"12","author":"M Magdi","year":"2022","unstructured":"Magdi M, Mostafa MR, Abusnina W, et al. A\u00a0systematic review and meta-analysis of the prevalence of transthyretin amyloidosis in heart failure with preserved ejection fraction. Am J Cardiovasc Dis. 2022;12:102\u201311.","journal-title":"Am J Cardiovasc Dis"},{"key":"1954_CR2","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","volume":"6","author":"OF AbouEzzeddine","year":"2021","unstructured":"AbouEzzeddine OF, Davies DR, Scott CG, et al. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2021;6:1267\u201374.","journal-title":"JAMA Cardiol"},{"key":"1954_CR3","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","volume":"36","author":"E Gonz\u00e1lez-L\u00f3pez","year":"2015","unstructured":"Gonz\u00e1lez-L\u00f3pez E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a\u00a0cause of heart failure with preserved ejection fraction. Eur Heart\u00a0J. 2015;36:2585\u201394.","journal-title":"Eur Heart J"},{"key":"1954_CR4","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/ejhf.2894","volume":"25","author":"SD Anker","year":"2023","unstructured":"Anker SD, Usman MS, Anker MS, et al. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A\u00a0scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension. Eur J Heart Fail. 2023;25:936\u201355.","journal-title":"Eur J Heart Fail"},{"key":"1954_CR5","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1002\/ehf2.13360","volume":"8","author":"A Devesa","year":"2021","unstructured":"Devesa A, Camblor Blasco A, Pello LAM, et al. Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy. Esc Heart Fail. 2021;8:2856\u201365.","journal-title":"Esc Heart Fail"},{"issue":"8","key":"1954_CR6","first-page":"1885","volume":"2024","author":"P Garc\u00eda-Pav\u00eda","year":"2024","unstructured":"Garc\u00eda-Pav\u00eda P, Garc\u00eda-Pinilla JM, Lozano-Bahamonde A, et al. Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study. Rev Esp Cardiol. 2024;2024(8):1885\u2013585700240.","journal-title":"Rev Esp Cardiol"},{"key":"1954_CR7","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ejhf.2140","volume":"23","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis. A\u00a0position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail. 2021;23:512\u201326.","journal-title":"Eur J Heart Fail"},{"key":"1954_CR8","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1080\/00015385.2021.1976450","volume":"77","author":"P Debonnaire","year":"2022","unstructured":"Debonnaire P, Claeys M, De Smet M, et al. Trends in diagnosis, referral, red flag onset, patient profiles and natural outcome of de novo cardiac amyloidosis and their multidisciplinary implications. Acta Cardiol. 2022;77:791\u2013804.","journal-title":"Acta Cardiol"},{"key":"1954_CR9","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s00380-024-02408-3","volume":"39","author":"A Achten","year":"2024","unstructured":"Achten A, van Empel VPM, Weerts J, et al. Changes in the diagnostic trajectory of transthyretin cardiac amyloidosis over six years. Heart Vessels. 2024;39:857\u201366.","journal-title":"Heart Vessels"},{"key":"1954_CR10","doi-asserted-by":"publisher","unstructured":"Muller SA, Achten A, van der Meer MG, et al. Absence of an increased wall thickness does not rule out cardiac amyloidosis. Amyloid. 2024; https:\/\/doi.org\/10.1080\/13506129.2024.2348681","DOI":"10.1080\/13506129.2024.2348681"},{"key":"1954_CR11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.cjca.2024.10.010","volume":"41","author":"P Remior-P\u00e9rez","year":"2025","unstructured":"Remior-P\u00e9rez P, G\u00f3mez-Molina M, Garc\u00eda-Rodr\u00edguez D, et al. Prevalence of Cardiac Amyloidosis Among Elderly Patients With Recent-Onset Atrial Fibrillation: The PREVAL-ATTR Study. Can J Cardiol. 2025;41:167\u201377.","journal-title":"Can J Cardiol"},{"key":"1954_CR12","doi-asserted-by":"publisher","first-page":"357","DOI":"10.14740\/cr1436","volume":"13","author":"S Arshad","year":"2022","unstructured":"Arshad S, Goldberg YH, Bhopalwala H, et al. High Prevalence of Cardiac Amyloidosis in Clinically Significant Aortic Stenosis: A\u00a0Meta-Analysis. Cardiol Res. 2022;13:357\u201371.","journal-title":"Cardiol Res"},{"key":"1954_CR13","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.jcmg.2023.05.002","volume":"16","author":"X Arana-Achaga","year":"2023","unstructured":"Arana-Achaga X, Goena-Vives C, Villanueva-Benito I, et al. Development and Validation of a\u00a0Prediction Model and Score for Transthyretin Cardiac Amyloidosis Diagnosis: T-Amylo. JACC Cardiovasc Imaging. 2023;16:1567\u201380.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1954_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.5334\/gh.1262","volume":"18","author":"D Brito","year":"2023","unstructured":"Brito D, Albrecht FC, de Arenaza DP, et al. World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). gh. 2023;18:59.","journal-title":"gh"},{"key":"1954_CR15","volume-title":"WHO methods and data sources for country-level causes of death 2000\u20132019","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. WHO methods and data sources for country-level causes of death 2000\u20132019. Global Health Estimates Technical Paper WHO\/DDI\/DNA\/GHE\/20202; 2020."},{"key":"1954_CR16","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.jaccao.2023.05.012","volume":"5","author":"P Debonnaire","year":"2023","unstructured":"Debonnaire P, Claeys M, De Paepe P, et al. Prospective Screening for Transthyretin Cardiac Amyloidosis in Spinal Stenosis Surgery Patients: Results of the CASS Study. Jacc Cardiooncol. 2023;5:836\u20138.","journal-title":"Jacc Cardiooncol"},{"key":"1954_CR17","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1080\/13506129.2017.1375908","volume":"24","author":"J Rubin","year":"2017","unstructured":"Rubin J, Alvarez J, Teruya S, et al. Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier? Amyloid. 2017;24:226\u201330.","journal-title":"Amyloid"},{"key":"1954_CR18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jacc.2022.05.002","volume":"80","author":"C Zhang","year":"2022","unstructured":"Zhang C, Musikantow DR, Pugliese DN, et al. Chest-Wall Adipose Tissue Excisional Biopsy During Pacemaker or Defibrillator Implantation: New Technique to Diagnose Amyloidosis. J\u00a0Am Coll Cardiol. 2022;80:93\u20134.","journal-title":"J Am Coll Cardiol"},{"key":"1954_CR19","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore JD, Damy T, Fontana M, et al. A\u00a0new staging system for cardiac transthyretin amyloidosis. Eur Heart\u00a0J. 2018;39:2799\u2013806.","journal-title":"Eur Heart J"},{"key":"1954_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.15112","author":"L Healy","year":"2024","unstructured":"Healy L, Giblin G, Gray A, et al. Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction. Esc Heart Fail. 2024; https:\/\/doi.org\/10.1002\/ehf2.15112.","journal-title":"Esc Heart Fail"},{"key":"1954_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10741-020-10010-8","volume":"26","author":"M Bruno","year":"2021","unstructured":"Bruno M, Casta\u00f1o A, Burton A, Grodin JL. Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges. Heart Fail Rev. 2021;26:35\u201345.","journal-title":"Heart Fail Rev"},{"key":"1954_CR22","doi-asserted-by":"publisher","first-page":"2418965","DOI":"10.1080\/07853890.2024.2418965","volume":"56","author":"A Achten","year":"2024","unstructured":"Achten A, Muller SA, Wijk SS, et al. Diversity of heart failure phenotypes in transthyretin amyloid cardiomyopathy. More than just heart failure with preserved ejection fraction. Ann Med. 2024;56:2418965.","journal-title":"Ann Med"},{"key":"1954_CR23","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2303765","volume":"389","author":"P Garcia-Pavia","year":"2023","unstructured":"Garcia-Pavia P. Aus dem Siepen F, Donal E, et\u00a0al. Phase\u00a01 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid. N\u00a0Engl J Med. 2023;389:239\u201350.","journal-title":"N Engl J Med"}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-025-01954-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12471-025-01954-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-025-01954-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T11:18:12Z","timestamp":1747912692000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12471-025-01954-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1954"],"URL":"https:\/\/doi.org\/10.1007\/s12471-025-01954-3","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"value":"1568-5888","type":"print"},{"value":"1876-6250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"assertion":[{"value":"20 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.\u00a0Achten and C.\u00a0Knackstedt have received speaker\u2019s honoraria from Pfizer paid to the Maastricht University Medical Centre. C.\u00a0Knackstedt has also received consulting fees from Pfizer, BMS and Alnylam paid to the Maastricht University Medical Centre. V.P.M.\u00a0van Empel, J.\u00a0Weerts, S.\u00a0Mourmans, H.-P.\u00a0Brunner-La\u00a0Rocca and S.\u00a0Sanders-van\u00a0Wijk declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}